Charles Viviano MD, PhD
Chief Medical Officer
OCEA/CDRH/FDA

Dr. Viviano is Chief Medical Officer in the Office of Clinical Evidence and Analysis (OCEA) in the Center for Devices and Radiological Health (CDRH) at the Food and Drug Administration. He is a board-certified Urologist. Upon joining the FDA in 2015, he was the sole Urology medical officer in CDRH, responsible for the clinical review of all urologic devices, including the first submissions for high intensity focused ultrasound devices for prostate ablation. He was on the NESTcc Data Quality subcommittee and the SPARED (prostate ablation) registry effort. He is also the principal investigator for an FDA-led project identifying patient preferences in prostate cancer treatment.

As OCEA CMO, he provides clinical perspective to OCEA's real world evidence and programmatic efforts. Prior to joining the FDA, he was an Assistant Professor in the Division of Urology at Duke University where his practice focused on General Urology and Men's Health. Prior to Duke, he was in private practice in Connecticut. He received his medical education at the University of Connecticut and his PhD in Toxicology from the University of North Carolina at Chapel Hill.